川芎嗪注射液辅助治疗对老年慢性肾脏病4期非透析患者肾功能和微炎症状态的影响  

Effects of ligustrazine injection adjuvant therapy on renal function and microinflammation in elderly patients with stage 4 chronic kidney disease without dialysis

作　　者：易建伟 何志红 杨立华 魏培丹 徐石张 杨宜 YI Jianwei;HE Zhihong;YANG Lihua;WEI Peidan;XU Shizhang;YANG Yi(Department of Nephrology,Yichun People's Hospital,Yichun,Jiangxi,336000,China)

机构地区：[1]宜春市人民医院肾内科,江西宜春336000

出　　处：《当代医学》2024年第19期82-85,共4页Contemporary Medicine

基　　金：江西省中医药管理局科技计划(2021A026)。

摘　　要：目的探讨川芎嗪注射液辅助治疗对老年慢性肾脏病(chronic kidney disease,CKD)4期非透析患者肾功能和微炎症状态的影响。方法选取2021年8月至2023年3月宜春市人民医院收治的60例老年CKD 4期非透析患者作为研究对象,采用简单随机分组法分为对照组和川芎嗪组,每组30例。对照组采用控制血压、优质蛋白低磷饮食、纠正贫血及服用尿毒清等常规治疗,川芎嗪组在对照组治疗的基础上给予川芎嗪注射液辅助治疗。比较两组肾功能[血肌酐(serum creatinine,SCr)、尿素(carbamide,BUN)、肾小球滤过率(glomerular filtration rate,GFR)、24 h尿蛋白水平]、炎症因子[白细胞介素-10(interleukin-10,IL-10)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(interleukin-6,IL-6)]水平、临床疗效和不良反应发生率。结果治疗后,川芎嗪组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组SCr、BUN、24 h尿蛋白水平均低于治疗前,GFR高于治疗前,且川芎嗪组SCr、BUN、24 h尿蛋白水平均低于对照组,GFR高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清IL-10、TNF-α和IL-6水平均低于治疗前,且川芎嗪组低于对照组,差异有统计学意义(P<0.05)。两组并发症发生率比较差异无统计学意义。结论川芎嗪注射液能够降低老年CKD 4期非透析患者炎症因子水平,改善肾功能,提高临床疗效,且不增加不良反应。Objective To investigate the effects of ligustrazine injection adjuvant therapy on renal function and microinflammation in elderly patients with stage 4 chronic kidney disease(CKD)without dialysis.Methods 60 elderly patients with stage 4 CKD without dialysis treated in Yichun People's Hospital from August 2021 to March 2023 were selected as the research subjects,and they were divided into the control group and the ligustrazine group by simple randomization method,with 30 cases in each group.The control group was treated with blood pressure control,diet of high quality protein and low phosphorus,anemia correction and uriduxin,the ligustrazine group was given adjuvant therapy with ligustrazine injection on the basis of the control group.The renal function(serum creatinine[SCr],carbamide[BUN],glomerular filtration rate[GFR],24 h urine protein level),inflammatory factors(interleukin-10[IL-10],tumor necrosis factor-α[TNF-α],interleukin-6[IL-6]),clinical efficacy and incidence of adverse reactions were compared between the two groups.Results After treatment,the total effective rate in the ligustrazine group was higher than that in the control group,and the difference was statistically significant(P<0.05).After treatment,SCr,BUN,24 h urinary protein levels of the two groups were lower than before treatment,GFR was higher than before treatment,SCr,BUN,24 h urinary protein levels in the ligustrazine group were lower than control group,GFR was higher than control group,the differences were statistically significant(P<0.05).After treatment,serum levels of IL-10,TNF-αand IL-6 of the two groups were lower than before treatment,and the ligustrazine group was lower than control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of complications between the two groups.Conclusion Ligustrazine injection can reduce the level of inflammatory factors of elderly stage 4 CKD without dialysis patients,improve renal function,improve clinical efficacy,and do not incre

关 键 词：川芎嗪注射液 老年慢性肾脏病4期非透析患者 白细胞介素-10 肿瘤坏死因子-Α 

分 类 号：R692[医药卫生—泌尿科学]